Roth Capital Expects Reduced Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Analysts at Roth Capital decreased their Q2 2025 earnings estimates for shares of Sensus Healthcare in a research note issued on Thursday, May 15th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $0.03 per share for the quarter, down from their previous forecast of $0.08. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share. Roth Capital also issued estimates for Sensus Healthcare's Q4 2025 earnings at $0.18 EPS, FY2026 earnings at $0.19 EPS and FY2027 earnings at $0.22 EPS.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. The business had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million.

Other research analysts have also issued research reports about the stock. Maxim Group cut their price target on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday. Lake Street Capital cut their target price on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Wall Street Zen downgraded Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Thursday. Finally, HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Sensus Healthcare in a report on Friday, April 4th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $11.67.

Sensus Healthcare Stock Up 0.2%

Shares of SRTS traded up $0.01 during mid-day trading on Monday, hitting $4.69. 41,205 shares of the company traded hands, compared to its average volume of 208,471. Sensus Healthcare has a 1-year low of $4.01 and a 1-year high of $9.33. The company has a market capitalization of $77.13 million, a PE ratio of 11.73 and a beta of 1.30. The business has a 50 day moving average of $4.61 and a 200 day moving average of $6.06.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc acquired a new stake in Sensus Healthcare during the 4th quarter worth about $95,000. NewEdge Advisors LLC acquired a new stake in Sensus Healthcare during the fourth quarter worth about $109,000. Arrowstreet Capital Limited Partnership grew its holdings in Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock worth $1,039,000 after acquiring an additional 67,269 shares during the period. Dimensional Fund Advisors LP grew its holdings in Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock worth $2,620,000 after acquiring an additional 88,953 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in Sensus Healthcare during the fourth quarter worth about $27,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.